Base business breakout buried under ibuprofen's ₹700 Crore anchor

On the surface this looks like a clean turnaround: PAT up 55% YoY, EBITDA a 18-quarter high, debt cut ₹135 Crore in a single quarter. But strip out the ibuprofen unit and the base business story is even more impressive—24% revenue growth, crossing a new ₹300+ Crore quarterly plateau that was ₹245–248 Crore just a year ago. The problem is that ibuprofen, having already consumed ₹700 Crore in deployed capital, continues to drag consolidated margins with indefinite -12% EBITDA losses (₹10–15 Crore quarterly). Management deferred the strategic review for a decision to September again, offering no new clarity on exit value or timeline.

The consolidated ₹381.6 Crore result masks a bifurcated performance. Base business—the non-ibuprofen API portfolio (50–60 products, 15–16 drive 75% of revenue)—delivered ₹307 Crore, up 24% YoY, with EBITDA of ₹72 Crore (23.5% margin on the base, target 25% ±1%). This is real momentum: capacity utilization 70% across three sites (Cuddalore, Bangalore, Ambernath) leaves room to scale. Management guided 10% growth from the base going forward; they're already at 24%, suggesting either sandbagged guidance or genuine confidence in sustaining high single-digits at minimum. Ibuprofen, meanwhile, remains a capital sink. Revenue ~₹77 Crore, EBITDA margin -12%, normalized to ₹10–15 Crore quarterly losses indefinitely. No improvement pathway is articulated. This isn't a turnaround unit; it's a normalized loss center, and the ₹700 Crore of capital is unlikely to be recovered in full. The Vizag facility, where ibuprofen is manufactured, remains mothballed pending the H1 FY27 strategic decision.

Consolidated margin: PAT of ₹16.3 Crore is 4.2% of revenue, well below the base business's 20%+ share. This gap—ibuprofen diluting the consolidated story by 2–3 percentage points of PAT margin—is the structural problem no efficiency gain can solve unless the capital is reallocated or ibuprofen exits.

Base business gross margin contracted to 51.3% in Q1 from 54%+ in prior quarters. Of the ₹30 Crore in revenue tied to cost pass-through (8% of consolidated revenue), about ₹17–18 Crore comes from West Asia solvent supply crisis—raw materials are up 30%, lines shut intermittently, and management is passing costs to customers. This is not purely organic growth; organic volume growth is closer to 18–19% YoY once pricing is stripped out. The question: how much of the ₹30 Crore price cushion persists as West Asia normalizes? Management guided that 52–55% gross margin is the comfortable range for base business, implying a reversion to 54–55% margin once cost inflation moderates. If the ₹17–18 Crore solvent pass-through is temporary and reverses in H2 FY27, base business margin could expand back to historical 25% EBITDA (vs. 23.5% delivered). But if it lingers or if raw material costs remain elevated, the margin ceiling comes down. This is the key watch for Q2.

The stock is down 20.63% from its all-time high of ₹647 and trading at ₹513.55—well below its 20-, 50-, and 200-day simple moving averages (₹546, ₹557, ₹532 respectively). RSI at 20.2 signals oversold conditions, typically a technical setup for mean reversion. But the price action post-announcement is telling: the day-1 decline of -6.07% has only partially recovered to -3.01% by day 5, suggesting the market's skepticism on ibuprofen resolution is hardening, not softening. The stock had rallied modestly ahead of the result before falling sharply on announcement, indicating the market was not convinced the base business beat would overcome the ibuprofen overhang.

Institutional flows are neutral-to-negative. FII ownership has declined steadily from 14.63% (Q1 FY26) to 11.33% (Q1 FY27)—a 330 basis point drift out over 18 months. DII, meanwhile, has nudged up slightly (2.59% → 3.78%) but from a thin base. Promoter holding stable at 42%. The bulk deal on July 10 (TPG Growth IV selling 3 lakh shares @ ₹573.20) deserves attention: TPG exited at a price 11.6% above the current level, suggesting exit into strength. The stock has fallen ₹59.65 since that bulk sale, validating whatever forward view TPG held at the time.

The technical oversold condition could trigger a near-term bounce, but the fundamental overhang (ibuprofen's ₹700 Cr deployment on -12% margins indefinitely) caps sustained upside. The market is pricing in that ibuprofen value recovery is minimal and weighing the base business accordingly. Re-rating depends entirely on Sep 2026 decision clarity—until that hinge pin moves, the stock will remain a debate between base business bulls and ibuprofen bears.

From here: base business EBITDA per quarter. Q1 was ₹72 Crore. Management targets ₹72+ Cr (25% margin on ₹300+ Cr revenue) sustainably. That number will answer whether the turnaround is real or a seasonally boosted one-timer. If base EBITDA stays at ₹70+ Cr sequentially, consolidated debt reduction and margin expansion follow. If it falls below ₹65 Cr, the bull thesis is in trouble.